Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of Buy by Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been assigned an average rating of “Buy” from the eleven brokerages that are presently covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the […]

Related Keywords

Canada ,United States ,Mike Ouimette ,Fernwood Investment Management ,Virtu Financial ,Nasdaq ,Pliant Therapeutics Inc ,Tekla Capital Management ,Securities Exchange Commission ,Cantor Fitzgerald ,Royal Bank ,Canaccord Genuity Group ,Pliant Therapeutics ,Get Free Report ,Genuity Group ,Therapeutics Trading Down ,Hans Hull ,Exchange Commission ,General Counsel Mike Ouimette ,Investment Management ,Capital Management ,Hill Capital Management ,Get Free ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Ratings ,Consensus ,